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Summary
Since the discovery and subsequent widespread use of antibiotics, a variety of bacte-
rial species of human and animal origin have developed numerous mechanisms that ren-
der bacteria resistant to some, and in certain cases to nearly all antibiotics. There are many
important pathogens that are resistant to multiple antibiotic classes, and infections caused
by multidrug resistant (MDR) organisms are limiting treatment options and compromising
effective therapy. So the emergence of antibiotic-resistant pathogens in bacterial popula-
tions is a relevant field of study in molecular and evolutionary biology, and in medical
practice. There are two main aspects to the biology of antimicrobial resistance. One is con-
cerned with the development, acquisition and spread of the resistance gene itself. The ot-
her is the specific biochemical mechanism conveyed by this resistance gene. In this review
we present some recent data on molecular mechanisms of antibiotic resistance.
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Introduction
Infections have been the major cause of disease
throughout the history of human population. With the
introduction of antibiotics, it was thought that this prob-
lem should disappear. However, bacteria have been able
to evolve to become resistant to antibiotics (1–3). The in-
crease in antibiotic resistance has been attributed to a
combination of microbial characteristics, the selective
pressure of antibiotic use and social and technical chan-
ges that enhance the transmission of resistant organisms.
The growing threat from resistant organisms calls for
concerted action to prevent the emergence of new resis-
tant strains and the spread of existing ones (4).
Recent extensive reviews on the application of anti-
biotics in human and veterinary medicine (5–7), agricul-
ture (8) and aquaculture (9) have documented the en-
richment of antibiotic-resistant bacteria. Many procedures,
use and misuse of antibiotics in man have resulted in
antibiotic-resistant bacteria. The nutritive and therapeu-
tic antibiotic treatment of farm animals amounts to a half
of the world’s antibiotic output and has also resulted in
antibiotic-resistant bacteria. Evidence is accumulating to
support the hypothesis that antibiotic-resistant bacteria
from poultry, pigs and cattle enter the food supply, can
be found in human food (10–13), colonize human diges-
tive tract and transfer resistance genes to human com-
mensals.
There have been very few systematic studies to in-
vestigate the acquired antibiotic resistance in lactic acid
bacteria (LAB) of food origin. However, they are lately
expanding due to increased interest in probiotic lactic
acid bacteria and genetic modification of LAB. When
LAB live in a biotope regularly challenged by antibiotics
(human or animal intestine, bovine udder), the acquired
11S. D@IDI] et al.: Antibiotic Resistance in Bacteria, Food Technol. Biotechnol. 46 (1) 11–21 (2008)
*Corresponding author; Phone: ++385 1 4605 291; Fax: ++385 1 4836 424; E-mail: jsusko@pbf.hr
antibiotic resistance is found in Enterococcus, Lactococcus
and Lactobacillus species (14–16). The resistant bacteria may
interact with the resident human microflora and possi-
bly transfer or acquire antibiotic resistance determinants
by horizontal gene transfer. Large numbers of probiotic
bacteria are consumed to maintain and restore the mi-
crobial balance in the intestines. It must be kept in mind
that they have a potential to transfer antibiotic resistan-
ces to pathogenic bacteria. For these and other applica-
tions the safety aspects of these bacteria are of concern,
including the presence of potentially transferable antibi-
otic resistances (14–17).
Bacteria that normally reside in the human colon
can transfer resistance genes among themselves (18–21).
This type of transfer becomes a huge problem when
these harmless commensal bacteria transform into patho-
gens (22). The environment is replete with drug resis-
tance genes, among both pathogen and commensal bac-
teria. Once acquired, resistance genes are not easily lost.
Instead, they become a relatively stable part of a ge-
nome. Additional resistance determinants may join those
already prevailing, thus broadening the multidrug resis-
tance phenotype and further diminishing treatment op-
tions (23–25). An increasing number of bacterial isolates
is resistant to practically all available therapeutic agents.
Multidrug resistance has been demonstrated in Escheri-
chia coli, Salmonella enterica serovar Typhimurium, Shigel-
la dysenteriae, Enterococcus faecium, Staphylococcus aureus,
Mycobacterium tuberculosis, Haemophilus influenzae, Pseu-
domonas aeruginosa, Klebsiella pneumoniae, Acinetobacter
baumannii, Stenotrophomonas maltophilia, Xanthomonas and
Burkholderia (26).
Thus, the emergence of antibiotic resistance in bac-
terial populations is a relevant field of study in molecu-
lar and evolutionary biology as well as in medical prac-
tice. Here we present recent data on bacterial resistance
to antibiotics. We will focus on the molecular mecha-
nisms of antibiotic resistance and genetic parameters in-
volved in development, acquisition and spread of resis-
tance genes.
Modes of Antibiotic Action
Three conditions must be met for an antibiotic to be
effective against bacteria: i) a susceptible antibiotic tar-
get must exist in the cell, ii) the antibiotic must reach the
target in sufficient quantity, and iii) the antibiotic must
not be inactivated or modified (27,28).
Understanding antibiotic resistance mechanisms re-
quires an understanding of where antibiotics exert their
effect. There are five major modes of antibiotic mecha-
nisms of activity and here are some examples.
Interference with cell wall synthesis
b-lactam antibiotics such as penicillins and cephalo-
sporins interfere with enzymes required for the synthe-
sis of the peptidoglycan layer. Glycopeptides (vancomy-
cin, teicoplanin, oritavancin) target the bacterial cell wall
by binding to the D-alanyl-D-alanine termini of the pep-
tidoglycan chain, thereby preventing the cross-linking
steps. Telavancin, a novel rapidly bactericidal lipoglyco-
peptide, inhibits peptidoglycan biosynthesis through
preferential targeting of transglycosylation (29,30).
Inhibition of protein synthesis
Macrolides bind to the 50S ribosomal subunit and
interfere with the elongation of nascent polypeptide
chains. Aminoglycosides inhibit initiation of protein syn-
thesis and bind to the 30S ribosomal subunit. Chlor-
amphenicol binds to the 50S ribosomal subunit blocking
peptidyltransferase reaction. Tetracyclines inhibit pro-
tein synthesis by binding to 30S subunit of ribosome,
thereby weakening the ribosome-tRNA interaction. The
semisynthetic tetracycline derivatives, colloquially termed
the glycylglycines, act at the bacterial ribosome to arrest
translation. The glycylglycines bind the ribosome more
tightly than previous tetracyclines, so that the TetM re-
sistance factor is unable to displace them from this site,
hence TetM is unable to protect the ribosomes from the
action of these new drugs. The TetA-mediated efflux
system is ineffective against the glycylglycines, as they
are not substrates for the transporter. The oxazolidino-
nes, one of the newest classes of antibiotics, interact with
the A site of the bacterial ribosome where they should
interfere with the placement of the aminoacyl-tRNA (29,
31).
Interference with nucleic acid synthesis
Rifampicin interferes with a DNA-directed RNA po-
lymerase. Quinolones disrupt DNA synthesis by inter-
ference with type II topoisomerases DNA gyrase and to-
poisomerase IV during replication and by causing double
strand breaks (29).
Inhibition of a metabolic pathway
The sulfonamides (e.g. sulfamethoxazole) and trime-
thoprim each block the key steps in folate synthesis,
which is a cofactor in the biosynthesis of nucleotides, the
building blocks of DNA and RNA (29).
Disorganizing of the cell membrane
The primary site of action is the cytoplasmic mem-
brane of Gram-positive bacteria, or the inner membrane
of Gram-negative bacteria. It is postulated that polymy-
xins exert their inhibitory effects by increasing bacterial
membrane permeability, causing leakage of bacterial con-
tent. The cyclic lipopeptide daptomycin displays rapid
bactericidal activity by binding to the cytoplasmic mem-
brane in a calcium-dependent manner and oligomeri-
zing in the membrane, leading to an efflux of potassium
from the bacterial cell and cell death (32,33).
Biochemistry of Antibiotic Resistance
Understanding the mechanisms of resistance has be-
come a significant biochemical issue over the past sev-
eral years and nowadays there is a large pool of infor-
mation about how bacteria can develop drug resistance
(34–36). Biochemical and genetic aspects of antibiotic re-
sistance mechanisms in bacteria are shown in Fig. 1.
Although the manner of acquisition of resistance
may vary among bacterial species, resistance is created
by only a few mechanisms: (i) Antibiotic inactivation –
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direct inactivation of the active antibiotic molecule (36);
(ii) Target modification – alteration of the sensitivity to
the antibiotic by modification of the target (37); (iii)
Efflux pumps and outer membrane (OM) permeability
changes – reduction of the concentration of drug with-
out modification of the compound itself (38); or (iv) Tar-
get bypass – some bacteria become refractory to specific
antibiotics by bypassing the inactivation of a given en-
zyme. This mode of resistance is observed in many trime-
thoprim- and sulfonamide-resistant bacteria. The exam-
ple is in bypassing inhibition of dihydrofolate reductase
(DHFR) and dihydropteroate synthase (DHPS) enzymes
(involved in tetrahydrofolate biosynthesis). They are in-
hibited by trimethoprim and sulfonamides, respectively.
In several trimethoprim- and sulfonamide-resistant strains,
a second enzyme that has low affinity for the inhibitors
is produced (34,39).
There is an amazing diversity of antibiotic resistance
mechanisms within each of these four categories and a
single bacterial strain may possess several types of resis-
tance mechanisms. Which of these mechanisms prevails
depends on the nature of the antibiotic, its target site,
the bacterial species and whether it is mediated by a re-
sistance plasmid or by a chromosomal mutation.
Antibiotic inactivation
The defence mechanisms within the category of an-
tibiotic inactivation include the production of enzymes
that degrade or modify the drug itself. Biochemical stra-
tegies are hydrolysis, group transfer, and redox mecha-
nisms.
Antibiotic inactivation by hydrolysis
Many antibiotics have hydrolytically susceptible che-
mical bonds (e.g. esters and amides). Several enzymes
are known to destroy antibiotic activity by targeting and
cleaving these bonds. These enzymes can often be ex-
creted by the bacteria, inactivating antibiotics before
they reach their target within the bacteria. The classical
hydrolytic amidases are the b-lactamases that cleave the
b-lactam ring of the penicillin and cephalosporin antibi-
otics. Many Gram-negative and Gram-positive bacteria
produce such enzymes, and more than 200 different
b-lactamases have been identified. b-Lactamases are
classified into four groups on the basis of functional
characteristics, including preferred antibiotic substrate.
Clinical isolates often produce b-lactamases belonging to
different functional groups. They can be both chromo-
somal and plasmid-encoded b-lactamases transferred
from different bacteria (40–43).
Extended-spectrum b-lactamases (ESBLs) mediate re-
sistance to all penicillins, third generation cephalospo-
rins (e.g. ceftazidime, cefotaxime, ceftriaxone) and az-
treonam, but not cephamycins (cefoxitin and cefotetan)
and carbapenems. ESBLs are very diverse: more than
180 different ESBLs have been identified. They are most
commonly detected in Escherichia coli, Klebsiella pneumo-
niae and Proteus mirabilis, but have also been found in
other Enterobacteriaceae (44,45). The website http://www.
lahey.org/Studies/ was established to standardize the no-
menclature for the growing number of b-lactamases and
provide references to sources for nucleotide and amino
acid sequence information (46).
Other hydrolytic enzyme examples include esterases
that have been linked to macrolide antibiotic resistance
and ring-opening epoxidases causing resistance to fos-
fomycin (47–49).
Antibiotic inactivation by group transfer
The most diverse family of resistant enzymes is the
group of transferases. These enzymes inactivate antibiot-
ics (aminoglycosides, chloramphenicol, streptogramin,
macrolides or rifampicin) by chemical substitution (ade-
nylyl, phosphoryl or acetyl groups are added to the pe-
riphery of the antibiotic molecule). The modified antibi-
otics are affected in their binding to a target. Chemical
strategies include O-acetylation and N-acetylation (50–
52), O-phosphorylation (53–55), O-nucleotidylation (56,57),
O-ribosylation (58), O-glycosylation, and thiol transfer.
These covalent modification strategies all require a co-
-substrate for their activity (ATP, acetyl-CoA, NAD+,
UDP-glucose, or glutathione) and consequently these
processes are restricted to the cytoplasm.
Antibiotic inactivation by redox process
The oxidation or reduction of antibiotics has been
infrequently exploited by pathogenic bacteria. However,
there are a few of examples of this strategy (59–61). One
is the oxidation of tetracycline antibiotics by the TetX
enzyme. Streptomyces virginiae, producer of the type A
streptogramin antibiotic virginiamycin M1, protects itself
from its own antibiotic by reducing a critical ketone
group to an alcohol at position 16.
Target modification
The second major resistance mechanism is the mod-
ification of the antibiotic target site so that the antibiotic
is unable to bind properly. Because of the vital cellular
functions of the target sites, organisms cannot evade
antimicrobial action by dispensing with them entirely.
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Fig. 1. Biochemical and genetic aspects of antibiotic resistance
mechanisms in bacteria
However, it is possible for mutational changes to occur
in the target that reduce susceptibility to inhibition
whilst retaining cellular function (62).
In some cases, the modification in target structure
needed to produce resistance requires other changes in
the cell to compensate for the altered characteristics of
the target. This is the case in the acquisition of the peni-
cillin-binding protein 2a (PBP2a) transpeptidase in Sta-
phylococcus aureus that results in resistance to methicillin
(methicillin-resistant S. aureus, MRSA) and to most other
b-lactam antibiotics. To save the efficiency of peptido-
glycan biosynthesis, PBP2a needs alterations in the com-
position and structure of peptidoglycan, which involves
functioning of a number of additional genes (39,63,64).
Peptidoglycan structure alteration
The peptidoglycan component of the bacterial cell
wall provides an excellent selective target for the antibi-
otics. It is essential for the growth and survival of most
bacteria. Consequently, enzymes involved in synthesis and
assembly of the peptidoglycan component of the bacte-
rial cell wall provide excellent targets for selective inhi-
bition. The presence of mutations in the penicillin-bind-
ing domain of penicillin-binding proteins (PBPs) results
in decreased affinity to b-lactam antibiotics. Alterations
among PBPs result in ampicillin resistance among En-
terococcus faecium, and penicillin resistance among Strep-
tococcus pneumoniae (65–67). Resistance to methicillin and
oxacillin in S. aureus is associated with acquisition of a
mobile genetic element called SCCmec, which contains
the mecA resistance gene. The mecA determinant encodes
PBP2a, a new penicillin-binding protein distinct from the
PBPs normally found in S. aureus. PBP2a is highly resis-
tant to inhibition by all clinically used b-lactams and re-
mains active to maintain cell wall synthesis at normally
lethal b-lactam concentrations (32).
Glycopeptides such as vancomycin inhibit cell wall
synthesis of Gram-positive bacteria by binding C-termi-
nal acyl-D-alanyl-D-alanine (acyl-D-Ala-D-Ala)-containing
residues in peptidoglycan precursors. Resistance is
achieved by altering the target site by changing the D-
-Ala-D-Ala to D-alanyl-D-lactate (D-Ala-D-Lac) or D-alanyl-
-D-serine (D-Ala-D-Ser) at the C-terminus, which inhibits
the binding of vancomycin (68-70). As a consequence,
the affinity of vancomycin for the new terminus is 1000
times lower than for the native peptidoglycan precursor
in the case of D-Ala-D-Lac. Dissemination of glycopep-
tide resistance in Gram-positive cocci can occur at the
level of the bacteria (clonal spread), replicons (plasmid
epidemics) or of the genes (transposons). Glycopeptide
(vancomycin) resistance can be intrinsic (VanC-type re-
sistance) or acquired, present only in certain isolates be-
longing to the same species (VanA, B, D, C, E and G
types of vancomycin resistance) (71).
Protein synthesis interference
A wide range of antibiotics interfere with protein
synthesis on different levels of protein metabolism. The
resistance to antibiotics that interfere with protein syn-
thesis (aminoglycosides, tetracyclines, macrolides, chlo-
ramphenicol, fusidic acid, mupirocin, streptogramins,
oxazolidinones) or transcription via RNA polymerase
(the rifamycins) is achieved by modification of the spe-
cific target (39).
The macrolide, lincosamide and streptogramin B
group of antibiotics block protein synthesis in bacteria
by binding to the 50S ribosomal subunit (72–74). Resis-
tance to these antibiotics is referred to as MLS(B) type
resistance and occurs in a wide range of Gram-positive
bacteria. It results from a post-transcriptional modifica-
tion of the 23S rRNA component of the 50S ribosomal
subunit (75). Mutations in 23S rRNA close to the sites of
methylation have also been associated with resistance to
the macrolide group of antibiotics in a range of organ-
isms. In addition to multiple mutations in the 23S rRNA,
alterations in the L4 and L22 proteins of the 50S subunit
have been reported in macrolide-resistant S. pneumoniae
(76). The mechanism of action of oxazolidinones (for ex-
ample, linezolid) involves multiple stages in the protein
synthesis (77). Although they bind to the 50S subunit,
the effects include inhibition of formation of the initia-
tion complex and interference with translocation of pep-
tidyl-tRNA from the A site to the P site. Resistance has
been reported in a number of organisms including en-
terococci and is linked to mutations in the 23S rRNA re-
sulting in decreased affinity for binding (78).
Mutations in the 16S rRNA gene confer resistance to
the aminoglycosides (79). Chromosomally acquired strep-
tomycin resistance in M. tuberculosis is frequently due to
mutations in the rpsL gene encoding the ribosomal pro-
tein S12. Microorganisms that produce aminoglycosides
have developed mechanism of high level antibiotic resis-
tance by posttranscriptional methylation of 16S rRNA in
the aminoglycoside binding site. This mechanism of re-
sistance has recently been reported in human pathogens
from nosocomial infections and animal isolates (80).
DNA synthesis interference
Fluoroquinolones interact with the DNA gyrase and
topoisomerase IV enzymes and prevent DNA replication
and transcription. Resistance is conferred by mutations
in specific regions of the structural genes that sufficient-
ly alter these enzymes preventing the binding of antibi-
otics (81,82). The most common mutations in this region
cause resistance through decreased drug affinity for the
altered gyrase–DNA complex (83–85).
Efflux pumps and outer membrane (OM) permeability
The efflux pumps are the membrane proteins that
export the antibiotics out of the cell and keep its intra-
cellular concentrations at low levels. Reduced outer mem-
brane (OM) permeability results in reduced antibiotic up-
take. The reduced uptake and active efflux induce low
level resistance in many clinically important bacteria (86).
Efflux pumps
Efflux pumps affect all classes of antibiotics, espe-
cially the macrolides, tetracyclines, and fluoroquino-
lones because these antibiotics inhibit different aspects
of protein and DNA biosynthesis and therefore must be
intracellular to exert their effect. Efflux pumps vary in
both their specificity and mechanism (87,88). Although
some are drug-specific, many efflux systems are multi-
drug transporters that are capable of expelling a wide
spectrum of structurally unrelated drugs, thus contribut-
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ing significantly to bacterial multidrug resistance (MDR)
(89). Inducible multidrug efflux pumps are responsible
for the intrinsic antibiotic resistance of many organisms,
and mutation of the regulatory elements that control the
production of efflux pumps can lead to an increase in
antibiotic resistance. For example, the MexAB-OprM eff-
lux pump in Pseudomonas aeruginosa is normally posi-
tively regulated by the presence of drugs, but mutations
in its regulator (mexR) lead to the overexpression of
MexAB-OprM, which confers increased resistance to an-
tibiotics such as b-lactams (90–92). Both Gram-positive
and Gram-negative bacteria can possess single-drug
and/or multiple drug efflux pumps (93,94).
Bacterial drug efflux transporters are currently clas-
sified into five families (95,96). The major facilitator su-
perfamily (MFS) and the adenosine triphosphate (ATP)-
-binding cassette (ABC) superfamily are very large and
the other three are smaller families: the small multidrug
resistance (SMR) family, the resistance-nodulation-cell di-
vision (RND) superfamily and the multidrug and toxic
compound extrusion (MATE) family. Efflux transporters
can be further classified into single or multicomponent
pumps (97–99). Single component pumps transport their
substrates across the cytoplasmic membrane. Multicom-
ponent pumps, found in Gram-negative organisms, func-
tion in association with a periplasmic membrane fusion
protein (MFP) component and an outer membrane pro-
tein (OMP) component, and efflux substrates across the
entire cell envelope.
Furthermore, the regulators of efflux systems may
be attractive drug targets themselves. The regulators in-
volved in efflux gene expression are either local or glo-
bal regulators. Many pump component-encoding ope-
rons contain a physically linked regulatory gene. Some
efflux pumps are known to be regulated by two-compo-
nent systems. These systems mediate the adaptive respon-
ses of bacterial cells to their environment. Expression of
various efflux pumps is also controlled by different glo-
bal regulators. So far, several global transcriptional acti-
vators, including MarA, SoxS and Rob, have been shown
to be involved in the regulation of expression of this sys-
tem (97–99).
Outer membrane (OM) permeability changes
Gram-negative bacteria possess an outer membrane
consisting of an inner layer containing phospholipids and
an outer layer containing the lipid A moiety of lipopoly-
saccharides (LPS). This composition of the outer mem-
brane (OM) slows down drug penetration, and transport
across the OM is achieved by porin proteins that form
water-filled channels. Drug molecules can penetrate the
OM employing one of the following modes: by diffusion
through porins, by diffusion through the bilayer or by
self-promoted uptake. The mode of entry employed by a
drug molecule largely depends on its chemical composi-
tion. For example, hydrophilic compounds either enter
the periplasm through porins (e.g. b-lactams) or self-pro-
moted uptake (aminoglycosides). Antibiotics such as b-
-lactams, chloramphenicol and fluoroquinolones enter the
Gram-negative outer membrane via porins. As such,
changes in porin copy number, size or selectivity will al-
ter the rate of diffusion of these antibiotics (100–104).
The role of LPS as a barrier to antibiotics is well
documented. Mutations in LPS that result in antibiotic
hypersusceptibility have been reported. Strains of E. coli
and S. enterica serovar Typhimurium defective in LPS
have been found to be at least 4-fold more susceptible to
erythromycin, roxithromycin, clarithromycin and azithro-
mycin than the wild-type strains (105,106).
Genetics of Antibiotic Resistance
Studies of a wide variety of bacterial pathogens have
identified numerous genetic loci associated with antibi-
otic resistance. For some types of resistance there is a
large diversity of responsible genetic determinants.
Resistance can be an intrinsic property of the bacte-
ria themselves or it can be acquired. Acquired bacterial
antibiotic resistance can result from a mutation of cellu-
lar genes, the acquisition of foreign resistance genes or a
combination of these two mechanisms. Thus, there are
two main ways of acquiring antibiotic resistance: i)
through mutation in different chromosomal loci and ii)
through horizontal gene transfer (i.e. acquisition of resis-
tance genes from other microorganisms). This raises sev-
eral questions about the evolution and ecology of antibi-
otic resistance genes. Phylogenetic insights into the evo-
lution and diversity of several antibiotic resistance genes
suggest that at least some of these genes have a long
evolutionary history of diversification that began well
before the ðantibiotic era’ (107).
Mutations
Spontaneous mutations
Exploring the origins of resistant mutants began
with the antibiotic era in 1940s, when researchers per-
formed classical experiments proving that mutations
conferring resistance to certain antibiotics arise prior to
or in the absence of any selective pressure. These muta-
tion events occur randomly as replication errors or an
incorrect repair of a damaged DNA in actively dividing
cells. They are called growth dependent mutations (spon-
taneous mutations) and present an important mode of
generating antibiotic resistance (108).
Antibiotic resistance occurs by nucleotide point mu-
tations which are at the same time growth permissive
and are able to produce a resistance phenotype (109).
For instance, quinolone resistance phenotype in Esche-
richia coli is a result of changes in at least seven posi-
tions in the gyrA gene, but in only three positions in the
parC gene (110,111). A variety of genes can be involved
in antibiotic resistance either because there are several
different targets, access, or protection pathways for the
antibiotic in the bacterial cell or because each pathway
requires the expression of several genes.
There is a substantial number of biochemical mecha-
nisms of antibiotic resistance that are based on mutatio-
nal events, like the mutations of the sequences of genes
encoding the target of certain antibiotics (for instance, re-
sistance to rifamicins and fluoroquinolones are caused
by mutations in the genes encoding the targets of these
two molecules, RpoB and DNA-topoisomerases, respec-
tively) (112,113). The variation in the expression of anti-
biotic uptake or of the efflux systems may also be modi-
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fied by mutation (for instance, the reduced expression or
absence of the OprD porin of P. aeruginosa reduces the
permeability of the cell wall to carbapenems) (114). Some
of the resistances associated with the uptake and efflux
systems are caused by mutations in regulatory genes or
their promoter regions (115,116). Also, the mutations
leading to increased expression of the efflux systems, in
general, confer resistance to multiple antibiotics (for ex-
ample, mutations in the Escherichia coli mar gene affect
the expression of about 60 different genes, including
down-regulation of OmpF and up-regulation of AcrAB)
(117). AcrAB is involved in the efflux of b-lactams, fluo-
roquinolones, chloramphenicol, and tetracycline. In P. aeru-
ginosa, mutation in mexR up-regulates the mexA-mexB-
-oprM operon and raises resistance to most b-lactams,
fluoroquinolones, tetracyclines, chloramphenicol and ma-
crolides (118). The overproduction of antibiotic-inactivat-
ing enzymes may also be achieved through mutational
events. Many Gram-negative microorganisms produce
chromosomal b-lactamases at low levels and mutations
producing up-regulation of their expression may lead to
the resistance to most cephalosporins.
In addition to these examples, there are some clini-
cally relevant pathogens for which plasmid- or transpo-
son-mediated mechanisms of resistance have not been
reported (Mycobacterium tuberculosis isolated in the in-
fected patients lacks the horizontal transfer mechanisms
and, consequently, can acquire antibiotic resistance by
mutation exclusively) (119). P. aeruginosa from the lungs
of patients with cystic fibrosis is almost impossible to
eradicate, mainly because of the development of resis-
tance to multiple antibiotics. In this particular environ-
ment resistance is achieved through chromosomal muta-
tions that are able to produce resistance to all antibiotics
used in clinical practice, without any acquisition of exog-
enous DNA (120).
Hypermutators
It has been widely accepted that mutation is the un-
avoidable consequence of errors produced in the DNA
replication process or of the failure of the error-avoid-
ance systems. Maintaining the stability of genetic infor-
mation is vital for the perpetuation of species. Low spon-
taneous mutation rates are maintained by the activity of
many molecular mechanisms that protect and repair DNA,
as well as by the mechanisms that assure high-fidelity of
DNA replication (121,122). However, bacteria with an el-
evated mutation rate (hypermutable strains, or mutators)
among natural and laboratory populations have been
found. Experimental studies indicate that the frequency
of mutators observed among natural and clinical bacte-
rial isolates is much higher than expected, which sug-
gests that there are situations in nature where being a
mutator confers a selective advantage. According to the
currently most acceptable ðhypermutable state’ model,
during a prolonged non-lethal antibiotic selective pres-
sure a small bacterial population enters a transient state
of a high mutation rate. If a cell in this hypermutable
state achieves a useful mutation, thus relieving the se-
lective pressure, the cell begins to grow and reproduce,
and at the same time exits the hypermutable state. It is
still unclear what really triggers cells to enter the hyper-
mutable state; however, it appears that a hypermutation
is regulated by a special SOS-inducible mutator DNA po-
lymerase (pol) IV (108). Hypermutators have been found
in populations of E. coli, Salmonella enterica, Neisseria me-
ningitidis, Haemophilus influenzae, Staphylococcus aureus,
Helicobacter pylori, Streptococcus pneumoniae, P. aeruginosa
with frequencies ranging from 0.1 to above 60 % (123,
124).
Mutator phenotypes of different strengths could be
created by inactivation of over 20 different E. coli genes
(125,126). But the majority of strong mutators found in
the laboratory and in nature have a defective mismatch
repair (MMR) system due to the inactivation of mutS or
mutL genes (127). This repair system controls the fidelity
of DNA replication by eliminating biosynthetic errors. In
addition, the mismatch repair system is involved in the
maintenance of chromosomal structural integrity and in
the control of horizontal gene transfer by preventing re-
combination between non-identical DNA sequences (128).
The results of various studies have shown that mutators
play an important role in the evolution of antibiotic re-
sistance (112,129–131). By increasing the possibility of
mutations, they may accelerate the evolution of favour-
able mutations under certain conditions. During this
process, mutators can be fixed in the population by get-
ting along with the favourable mutations (e.g. resistance)
they have created. Thus, the acquisition of a mutator
phenotype may increase the chance of acquiring antibi-
otic resistance by mutational events. Hypermutators may
also enable multiresistant phenotype (132).
Adaptive mutagenesis
The mutation process has classically been studied in
actively dividing bacteria, as it was assumed that most
mutations occur as the consequence of errors during the
DNA replication process (spontaneous mutations). How-
ever, more recent experimental data have clearly shown
that mutations arise also in non-dividing or slowly di-
viding cells and have some relation to the selective pres-
sure used. These mutations, named ðadaptive mutations’,
arise only in the presence of non-lethal selective pres-
sure that favours them. This is the main feature that dis-
tinguishes them from the growth dependent, spontane-
ous mutations. The adaptive mutation process may be
one of the main sources of the antibiotic resistant mu-
tants under natural conditions (108,133,134). Analyses of
several model systems have demonstrated that stress-en-
hanced bacterial mutagenesis is a regulated phenome-
non (135,136). The main factors in this process are stress-
-responsive (as a part of finely regulated SOS response)
error-prone DNA polymerases V (umuCD) and IV (dinB),
which transiently increase the rate of mutation.
It has been demonstrated that some antibiotics (qui-
nolones, for example) are able to induce the SOS mu-
tagenic response and increase the rate of emergence of
resistance in E. coli (137). The emergence of multiresis-
tant strains increases in P. aeruginosa under antibiotic
challenge (138). E. coli exposed to antibiotic streptomycin
displays a hypermutable phenotype (139).
Some of adaptive mutations generated in mutator
backgrounds (antibiotic resistance, for example) can be
saved and fixed in a bacterial population either by hori-
zontal transfer to a non-mutator background or by a re-
duction in the mutation rate of the adapted mutator
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strain before the load of deleterious mutations becomes
too high. And then, the reduction of mutation rate
might be achieved by several mechanisms: reversion of
the mutator allele, acquisition of suppressor mutations
or by reacquisition of a wild-type allele of mutator gene
from non-mutator bacteria via horizontal gene exchange.
Horizontal gene transfer
A principal mechanism for the spread of antibiotic
resistance is by horizontal transfer of genetic material.
Antibiotic resistance genes may be transferred by differ-
ent mechanisms of conjugation, transformation, or trans-
duction. Resistance genes can be further incorporated
into the recipient chromosome by recombination. These
genes may contain single mutations or more severe se-
quence changes.
Tetracycline resistance in most bacteria is due to the
acquistion of new genes often associated with mobile
elements. These genes are usually associated with plas-
mids and/or transposons and are often conjugative. The
website http://faculty.washington.edu/marilynr/, which is
updated twice a year, was established to reflect the on-
going changes in information on acquired tetracycline
resistance (tet) and oxytetracycline resistance (otr) genes,
originally in antibiotic producing Streptomyces (140,141).
Among Gram-negative anaerobes and Gram-positive
bacteria, conjugative transposons are recognized as im-
portant mediators of genetic exchange on a par with the
large R-plasmids of enteric bacteria. These large (>25 kb)
elements encode a fully functional conjugation appara-
tus and are capable of self-transfer to a wide variety of
species. Conjugative transposons in the Bacterioides are
referred to as Tcr-elements (tetracycline resistance ele-
ments) owing to the presence of tetracycline resistance
genes (tetQ) and these elements are primarily responsi-
ble for more than 80 % of tetracycline resistance frequen-
cy among Bacteroides clinical isolates (142). High level re-
sistance to gentamicin and all other related aminogly-
cosides with the exception of streptomycin, was found
in enterococci. The gene conferring this phenotype has
been associated with both narrow and broad host range
plasmids. The nature of these conjugative elements raises
the possibility of the resistance gene spreading to other
pathogenic bacteria (143).
Horizontal transfer of resistance genes is a mecha-
nism for the dissemination of multiple drug resistance
because resistance genes can be found in clusters and
transferred together to the recipient. This is enabled by
the existence of specific DNA structures called integrons
(144,145). Integrons are DNA elements with the ability
to capture genes, notably those encoding antibiotic resis-
tance, by site-specific recombination. These elements are
located either on the bacterial chromosome or on broad
host range plasmids. Integrons differ from transposons
in two important characteristics: transposons have direct
or indirect repeat sequences at their ends, but the re-
gions surrounding the antibiotic resistance genes in the
integrons are not repeats; and the integrons contain a
site specific integrase gene of the same family as those
found in phages but lack gene products associated with
transposition. Integrons promote the capture of one or
more gene cassettes within the same attachment site
thereby forming clusters of antibiotic resistance genes.
Gene cassettes are the smallest mobile genetic entities
that can carry resistance determinants. These can encode
many types of resistance including to trimethoprim,
chloramphenicol, b-lactams, aminoglycosides, fosfomycin
and quinolones and for each of these antibiotic classes
several distinct gene cassettes have been reported. Resis-
tance gene cassettes have been found for the most clas-
ses of antibiotics, and the gene products are involved in
various mechanisms of resistance, such as efflux, target
bypass and drug inactivation. Over 40 gene cassettes and
three distinct classes of integrons have been identified to
date (146).
Integron movement allows transfer of the cassette-
-associated resistance genes from one DNA replicon to
another. Horizontal transfer of the resistance genes can
be achieved when an integron is incorporated into a
broad host range plasmid. A plasmid with a pre-existing
resistance gene cassette can acquire additional resistance
gene cassettes from donor plasmids, thus spreading mul-
tiresistance. All resistance-encoding DNAs establish a
resistance gene pool, which represents a potential source
for the horizontal transfer between bacteria. There are
many examples of horizontal gene transfer of resistance
elements both within and between bacterial species (23,
147). Studies about horizontal gene transfer-emerging
multidrug resistance in hospital bacteria have demon-
strated that the transfer of antibiotic resistance genes can
take place in the intestine between Gram-positive or
Gram-negative bacilli (23).
Multidrug-resistance (MDR) in bacteria is often the
result of the acquisition of mobile genetic elements that
contain multiple resistance genes. Nucleotide sequence
analysis of multiresistant integrons shows that the in-
serted resistance gene cassettes differ markedly in codon
usage, indicating that the antibiotic resistance determi-
nants are of diverse origins (148). The fact that bacteria
that have been separately evolving for up to 150 million
years can exchange DNAs has strong implications with
regard to the evolution of antibiotic resistance in bacte-
rial pathogens (149–151).
Conclusion
Widespread use of antibiotics has undoubtedly caused
the epidemics of antimicrobial resistance worldwide.
Unfortunately, resistance in some species has developed
to the level that no clinically available treatment is effec-
tive. Prevention and control strategies will require the
application of epidemiological and behavioural ap-
proaches, as well as the research technologies aimed at
the basic mechanisms of drug resistance. The genetic
characterization of antimicrobial resistance genes as well
as their location and diversity is important in identify-
ing factors involved in resistance. It is also important to
identify genetic linkages among markers and to under-
stand potential transfer mechanisms. It appears that ex-
pression of bacterial resistance to antibiotics is fre-
quently regulated. Modulation of gene expression can
occur at the transcriptional or translational level follow-
ing mutations or the movement of mobile genetic ele-
ments. It may also involve induction of mutations or
gene transfer by the antibiotic so that the antibiotic can
have a triple activity: as an antibacterial agent, as an in-
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ducer of resistance to itself, and as an inducer of the dis-
semination of resistance determinants. Bacteria have ela-
borated mechanisms to achieve antibiotic resistance by
the fine-tuning of the expression of genetic information.
Knowledge of the molecular mechanisms of antibio-
tic resistance is essential for developing new approaches
to overcome this problem. One possible approach is the
development of inhibitors of resistance enzymes. These
inhibitors can be administered as co-drugs with the anti-
biotics, thereby blocking resistance and rescuing the
antimicrobial activity of the drugs. Another strategy to
overcome resistance is to improve the delivery or other-
wise enhance the accessibility of antibiotics to their sites
of action. For example, liposomal preparations of hydro-
phobic antibiotics, such as ethambutol for treatment of
mycobacterial infections, have been reported. Strategies
could be developed to target virulence factors of patho-
gens instead of whole bacteria (e.g. develop drugs that
target the plasmids containing resistance genes or drugs
that target the adhesion of virulent bacteria to a tissue).
All the alternative strategies to overcome resistance
require expanded knowledge of the molecular mecha-
nisms of antibiotic resistance, their origins and evolu-
tion, and their distribution throughout bacterial popula-
tions and genomes.
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